EWTX sentiment intelligence

Boulder biotech unloads muscular dystrophy drug for up to $2.65 billion

Boulder-based Edgewise Therapeutics has sold its muscular dystrophy drug for an upfront payment of $1.55 billion, with the potential to receive an additional $1.1 billion if certain regulatory and commercial milestones are met. The company went public on Nasdaq in 2021.

Tone

Positive 81/100

Event

Regulatory and legal

Published

13 Jul 2026 21:14

Source

The Business Journals

Edgewise completes sale of sevasemten to Servier for $2.65B

Edgewise Therapeutics Inc. has completed the sale of sevasemten and its muscular dystrophy business to Servier for $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in milestone payments. This transaction shifts Edgewise's strategic focus to cardiovascular dis

Tone

Positive 74/100

Event

Market update

Published

13 Jul 2026 16:39

Source

Investing.com

Positive Trial Results Propel Edgewise's (EWTX) Plans for Phase 3 Development

Tone

Positive 66/100

Event

Earnings

Published

13 Jul 2026 14:04

Source

GuruFocus

Edgewise Therapeutics Completes Up to $2.65 Billion Sevasemten Sale to Focus on Cardiovascular Pipeline

Edgewise Therapeutics Inc. has completed the sale of sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion, including $1.55 billion upfront. This strategic move allows Edgewise to focus entirely on its cardiovascular pipeline, advancing treatments for

Tone

Positive 71/100

Event

Market update

Published

13 Jul 2026 14:11

Source

citybiz

Edgewise sells sevasemten business for $1.55 billion

Edgewise Therapeutics has sold its sevasemten and muscular dystrophy business to Servier for an upfront cash payment of $1.55 billion and up to $1.1 billion in potential milestones. This transaction allows Edgewise to focus its resources on its cardiovascular pipeline, including

Tone

Positive 67/100

Event

Balance sheet

Published

13 Jul 2026 13:16

Source

grafa.com

[8-K] Edgewise Therapeutics, Inc. Reports Material Event

Edgewise Therapeutics, Inc. announced the completion of the sale of its sevasemten compound and muscular dystrophy program to Servier Pharmaceuticals and Les Laboratoires Servier for up to $2.65 billion, including $1.55 billion upfront. This transaction strengthens Edgewise's bal

Tone

Positive 77/100

Event

Market update

Published

13 Jul 2026 12:14

Source

Stock Titan

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

Servier has finalized its acquisition of Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion, which includes an upfront payment of $1.55 billion and up to $1.1 billion in milestone payments. This acquisition significantly enhances Servier's rare neurology p

Tone

Positive 71/100

Event

Deals and strategy

Published

13 Jul 2026 12:14

Source

PR Newswire

Muscular dystrophy drug sevasemten drives Servier’s $2.65B Edgewise buy

Servier has completed the acquisition of Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion, including an upfront payment of $1.55 billion and potential milestone payments. This deal secures sevasemten, a late-stage therapy for Becker muscular dystrophy an

Tone

Positive 74/100

Event

Deals and strategy

Published

13 Jul 2026 12:11

Source

Stock Titan

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Edgewise Therapeutics has announced the completion of the sale of its muscular dystrophy business, including sevasemten, to Servier for up to $2.65 billion. This transaction provides Edgewise with $1.55 billion in upfront cash and up to $1.1 billion in milestone payments, signifi

Tone

Positive 93/100

Event

Balance sheet

Published

13 Jul 2026 12:11

Source

PR Newswire

Is Edgewise Therapeutics (EWTX) on the Cusp of a Breakthrough Year

Edgewise Therapeutics (EWTX) is approaching a potentially transformative 2026 with critical clinical trial data readouts for its lead candidates, sevasemten and EDG-7500, targeting rare muscle and cardiac diseases. Investors are closely watching the Phase 3 data for sevasemten in

Tone

Positive 66/100

Event

Market update

Published

11 Jul 2026 11:10

Source

Kavout | AI

Oppenheimer Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $51

Oppenheimer has initiated coverage on Edgewise Therapeutics (EWTX.US) with a "Buy" rating. The firm has set a price target of $51 for the company's stock, indicating a positive outlook for its future performance. This suggests Oppenheimer believes Edgewise Therapeutics has signif

Tone

Positive 86/100

Event

Analyst action

Published

09 Jul 2026 22:41

Source

Moomoo

CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?

Tone

Positive 66/100

Event

Market update

Published

09 Jul 2026 20:13

Source

Stocktwits

Oppenheimer Initiates Edgewise Therapeutics at Outperform

Tone

Positive 58/100

Event

Analyst action

Published

09 Jul 2026 12:19

Source

MT Newswires

Oppenheimer initiates Edgewise Therapeutics stock with outperform rating

Oppenheimer has initiated coverage on Edgewise Therapeutics Inc. (NASDAQ:EWTX) with an Outperform rating and a price target of $51.00. The company, a clinical-stage biopharmaceutical firm, is developing therapies for hypertrophic cardiomyopathy and is fully funded through commerc

Tone

Positive 82/100

Event

Analyst action

Published

09 Jul 2026 12:10

Source

Investing.com

Edgewise Therapeutics stock hits all-time high at 43.96 USD

Edgewise Therapeutics stock reached an all-time high of $43.96, currently trading at $44.17 with a market capitalization of $4.66 billion. The stock has seen a 231% increase over the past year, driven by strong investor confidence and positive analyst updates. Several firms like

Tone

Positive 82/100

Event

Analyst action

Published

08 Jul 2026 17:09

Source

Investing.com

Edgewise Therapeutics stock hits all-time high at 43.96 USD By Investing.com

Edgewise Therapeutics Inc. (EWTX) stock reached an all-time high of $43.96, currently trading at $44.17 with a market capitalization of $4.66 billion. The stock has increased by 231% over the past year, reflecting strong investor confidence despite an InvestingPro suggestion that

Tone

Positive 69/100

Event

Market update

Published

08 Jul 2026 13:43

Source

Investing.com Canada

(EWTX) as a Liquidity Pulse for Institutional Tactics

This article analyzes Edgewise Therapeutics Inc. (NASDAQ: EWTX) for institutional strategies, highlighting a mid-channel oscillation pattern and a significant 38.8:1 risk-reward setup targeting an 11.1% gain. It presents three distinct AI-generated trading strategies—Position, Mo

Tone

Positive 71/100

Event

Balance sheet

Published

07 Jul 2026 06:08

Source

Stock Traders Daily

Guggenheim Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $51

Guggenheim has reiterated its Buy rating on Edgewise Therapeutics (EWTX.US) and increased its target price to $51. This positive adjustment likely reflects the analyst's continued confidence in the company's prospects and potential for growth.

Tone

Positive 80/100

Event

Analyst action

Published

06 Jul 2026 16:13

Source

Moomoo

Guggenheim raises Edgewise Therapeutics stock price target on Servier deal

Guggenheim raised its price target for Edgewise Therapeutics (NASDAQ:EWTX) to $51 from $41, maintaining a Buy rating after the planned sale of Edgewise's muscular dystrophy business unit to Servier for up to $2.65 billion. The upgrade was also supported by positive Phase 2 CIRRUS

Tone

Positive 72/100

Event

Analyst action

Published

06 Jul 2026 14:10

Source

Investing.com

Guggenheim raises Edgewise Therapeutics stock price target on Servier deal By Investing.com

Guggenheim has increased its price target for Edgewise Therapeutics (EWTX) to $51 from $41, maintaining a Buy rating, following the planned sale of Edgewise's muscular dystrophy unit to Servier for up to $2.65 billion. The firm also cited strong efficacy data for EDG-7500 in hype

Tone

Positive 80/100

Event

Analyst action

Published

06 Jul 2026 13:09

Source

Investing.com Canada

If You Invested $1,000 in Edgewise Therapeutics, Inc. (EWTX)

This article analyzes the historical performance of Edgewise Therapeutics, Inc. (EWTX) stock, detailing potential returns for $1,000 investments made one, five, and ten years ago, as well as since its IPO. It further provides an in-depth company overview, highlighting its focus o

Tone

Positive 81/100

Event

Market update

Published

04 Jul 2026 13:39

Source

Stock Titan